Senescence Drives Immunotherapy Resistance by Inducing an Immunosuppressive Tumor Microenvironment

Overview

Journal Nat Commun

Specialty Biology

Date 2024 Mar 19

PMID 38499573

Authors

Damien Maggiorani

Oanh Le

Veronique Lisi

Severine Landais

Gael Moquin-Beaudry

Vincent Philippe Lavallee

Helene Decaluwe

Christian Beausejour

Affiliations

Soon will be listed here.

Abstract

The potential of immune checkpoint inhibitors (ICI) may be limited in situations where immune cell fitness is impaired. Here, we show that the efficacy of cancer immunotherapies is compromised by the accumulation of senescent cells in mice and in the context of therapy-induced senescence (TIS). Resistance to immunotherapy is associated with a decrease in the accumulation and activation of CD8 T cells within tumors. Elimination of senescent cells restores immune homeostasis within the tumor micro-environment (TME) and increases mice survival in response to immunotherapy. Using single-cell transcriptomic analysis, we observe that the injection of ABT263 (Navitoclax) reverses the exacerbated immunosuppressive profile of myeloid cells in the TME. Elimination of these myeloid cells also restores CD8 T cell proliferation in vitro and abrogates immunotherapy resistance in vivo. Overall, our study suggests that the use of senolytic drugs before ICI may constitute a pharmacological approach to improve the effectiveness of cancer immunotherapies.

Citing Articles

Immunosenescence promotes cancer development: from mechanisms to treatment strategies.

Wang L, Tang D Cell Commun Signal. 2025; 23(1):128.

PMID: 40065335 PMC: 11892258. DOI: 10.1186/s12964-025-02082-6.

The complex interplay between aging and cancer.

Trastus L, dAdda di Fagagna F Nat Aging. 2025; .

PMID: 40038418 DOI: 10.1038/s43587-025-00827-z.

Molecular Biomarkers in Borderline Ovarian Tumors: Towards Personalized Treatment and Prognostic Assessment.

Drymiotou S, Theodorou E, Rallis K, Nicolaides M, Sideris M Cancers (Basel). 2025; 17(3).

PMID: 39941911 PMC: 11816664. DOI: 10.3390/cancers17030545.

Development and experimental validation of a senescence-related long non-coding RNA signature for prognostic prediction and immune microenvironment characterization in gastric cancer patients.

Shi J, Hou Z, Fan L, Hu C, Ma N, Huang E J Gastrointest Oncol. 2025; 15(6):2413-2436.

PMID: 39816024 PMC: 11732332. DOI: 10.21037/jgo-24-792.

The crosstalk between senescence, tumor, and immunity: molecular mechanism and therapeutic opportunities.

Wang Z, Chen C, Ai J, Gao Y, Wang L, Xia S MedComm (2020). 2025; 6(1):e70048.

PMID: 39811803 PMC: 11731108. DOI: 10.1002/mco2.70048.

References

Thumkeo D, Punyawatthananukool S, Prasongtanakij S, Matsuura R, Arima K, Nie H . PGE-EP2/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment. Cell Rep. 2022; 39(10):110914. DOI: 10.1016/j.celrep.2022.110914. View

Zhang C, Lei L, Yang X, Ma K, Zheng H, Su Y . Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice. J Immunother Cancer. 2021; 9(10). PMC: 8513495. DOI: 10.1136/jitc-2021-002809. View

Marcoux S, Le O, Langlois-Pelletier C, Laverdiere C, Hatami A, Robaey P . Expression of the senescence marker p16INK4a in skin biopsies of acute lymphoblastic leukemia survivors: a pilot study. Radiat Oncol. 2013; 8:252. PMC: 3827993. DOI: 10.1186/1748-717X-8-252. View

Chang J, Wang Y, Shao L, Laberge R, Demaria M, Campisi J . Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med. 2015; 22(1):78-83. PMC: 4762215. DOI: 10.1038/nm.4010. View

Vu S, Vetrivel P, Kim J, Lee M . Cancer Resistance to Immunotherapy: Molecular Mechanisms and Tackling Strategies. Int J Mol Sci. 2022; 23(18). PMC: 9513751. DOI: 10.3390/ijms231810906. View

Yousefzadeh M, Zhu Y, McGowan S, Angelini L, Fuhrmann-Stroissnigg H, Xu M . Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018; 36:18-28. PMC: 6197652. DOI: 10.1016/j.ebiom.2018.09.015. View

Demaria M, OLeary M, Chang J, Shao L, Liu S, Alimirah F . Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse. Cancer Discov. 2016; 7(2):165-176. PMC: 5296251. DOI: 10.1158/2159-8290.CD-16-0241. View

Jang J, Kim D, Lim J, Lee J, Jeong S, Kim K . Breast Cancer Cell-Derived Soluble CD44 Promotes Tumor Progression by Triggering Macrophage IL1β Production. Cancer Res. 2020; 80(6):1342-1356. DOI: 10.1158/0008-5472.CAN-19-2288. View

Al-Habsi M, Chamoto K, Matsumoto K, Nomura N, Zhang B, Sugiura Y . Spermidine activates mitochondrial trifunctional protein and improves antitumor immunity in mice. Science. 2022; 378(6618):eabj3510. DOI: 10.1126/science.abj3510. View

10.

Kwart D, He J, Srivatsan S, Lett C, Golubov J, Oswald E . Cancer cell-derived type I interferons instruct tumor monocyte polarization. Cell Rep. 2022; 41(10):111769. DOI: 10.1016/j.celrep.2022.111769. View

11.

Palacio L, Goyer M, Maggiorani D, Espinosa A, Villeneuve N, Bourbonnais S . Restored immune cell functions upon clearance of senescence in the irradiated splenic environment. Aging Cell. 2019; 18(4):e12971. PMC: 6612633. DOI: 10.1111/acel.12971. View

12.

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

13.

Moquin-Beaudry G, Benabdallah B, Maggiorani D, Le O, Li Y, Colas C . Autologous humanized mouse models of iPSC-derived tumors enable characterization and modulation of cancer-immune cell interactions. Cell Rep Methods. 2022; 2(1):100153. PMC: 9017190. DOI: 10.1016/j.crmeth.2021.100153. View

14.

Sceneay J, Goreczny G, Wilson K, Morrow S, DeCristo M, Ubellacker J . Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer. Cancer Discov. 2019; 9(9):1208-1227. PMC: 11167954. DOI: 10.1158/2159-8290.CD-18-1454. View

15.

Li L, Song S, Fang X, Cao D . Role of ATF3 as a prognostic biomarker and correlation of ATF3 expression with macrophage infiltration in hepatocellular carcinoma. BMC Med Genomics. 2021; 14(1):8. PMC: 7789720. DOI: 10.1186/s12920-020-00852-4. View

16.

Fejza A, Polano M, Camicia L, Poletto E, Carobolante G, Toffoli G . The Efficacy of Anti-PD-L1 Treatment in Melanoma Is Associated with the Expression of the ECM Molecule EMILIN2. Int J Mol Sci. 2021; 22(14). PMC: 8306837. DOI: 10.3390/ijms22147511. View

17.

Wang S, Xie K, Liu T . Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters. Front Immunol. 2021; 12:690112. PMC: 8335396. DOI: 10.3389/fimmu.2021.690112. View

18.

Postmus A, Kruit J, Eilers R, Havinga R, Koster M, Johmura Y . The chemotherapeutic drug doxorubicin does not exacerbate p16-positive senescent cell accumulation and cardiometabolic disease development in young adult female LDLR-deficient mice. Toxicol Appl Pharmacol. 2023; 468:116531. DOI: 10.1016/j.taap.2023.116531. View

19.

Huseni M, Wang L, Klementowicz J, Yuen K, Breart B, Orr C . CD8 T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Rep Med. 2023; 4(1):100878. PMC: 9873827. DOI: 10.1016/j.xcrm.2022.100878. View

20.

Robert C . A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020; 11(1):3801. PMC: 7393098. DOI: 10.1038/s41467-020-17670-y. View